

# Filgotinib Marks Expansion into Inflammation with Potential for 5 Launches in Next 4 Years

**Filgotinib**

Selective JAK-1 inhibitor with **potential best-in-class profile**

**Strong efficacy for remission and demonstrated safety** at both doses; favorable benefit/risk profile at high dose

**Submitted for RA in U.S., Europe and Japan**

**P3 UC data in H1 2020**



Prepared for competitive RA launch with highly experienced team

13 RA - Rheumatoid Arthritis, UC - Ulcerative Colitis, CD - Crohn's Disease, PsA - Psoriatic Arthritis, AS - Ankylosing Spondylitis


# Building a Broad Inflammation and Fibrosis Portfolio with Galapagos Beyond Filgotinib




**Galapagos**  
Doubles Gilead's R&D footprint and accelerates transformational therapy development

8 clinical programs<sup>1</sup>

>20 pre-clinical programs



Selected programs



Key: **Fibrotic Diseases**; **Inflammatory Diseases**

1 Excluding filgotinib. 2 Autotaxin inhibitor. 3 GPR84 antagonist. 4 Toledo – dual mechanism anti-inflammatory. IPF - Idiopathic Pulmonary Fibrosis, OA - Osteoarthritis. Selected pre-clinical and P1 assets displayed.

14